Compounded Semaglutide in 2026: Is It Still Worth It After the FDA Shortage Ended?

Semaglutide came off the FDA drug-shortage list in February 2025. That removed the blanket 503A/503B authority to mass-compound copies of Wegovy and Ozempic. But compounding never became illegal — it just narrowed back to its original scope: patient-specific prescriptions where the commercial product isn't clinically appropriate.

In practice, that means a clinician can still prescribe compounded semaglutide when you have a documented intolerance to an inactive ingredient, need a non-standard dose for titration, or require a combination product (e.g., semaglutide + B12). It cannot be prescribed simply because it's cheaper.

Reputable telehealth programs charge $199–$329/mo all-in for compounded semaglutide, including the consult, the medication, and shipping. Tirzepatide compounds run $349–$499/mo.

Anything under $150/mo is a red flag. Sterile-injectable compounding from a licensed 503B outsourcing facility costs the pharmacy roughly $80–120 per vial in raw materials and QA — pricing below that usually means an offshore API source or a 503A pharmacy operating outside its legal patient-specific scope.

Check the registration

All US compounding pharmacies are listed in the FDA's 503A and 503B registries. A legitimate program will name its pharmacy partner on its FAQ page. Cross-check the name in the FDA database before you sign up.

Ask for the COA

Every batch of injectable compound should have a Certificate of Analysis showing identity, potency, sterility, and endotoxin results. Reputable programs (e.g., Henry Meds, Mochi Health, Eden) will provide one on request.

Avoid 'research peptides'

If a website sells semaglutide labeled 'not for human use' or 'research only,' it is not a pharmacy. It is selling unregulated bulk API that bypasses every safety check.

Our editorial team currently recommends Medvi, TrimRX, and Mochi Health for compounded GLP-1 access. All three use named 503A or 503B partners, publish their dosing schedules, and include real clinician oversight rather than rubber-stamp prescriptions.